Anti-cancer compound screening identifies Aurora Kinase A inhibition as a means to favor CRISPR/Cas9 gene correction over knock-out

Danny Wilbie; Selma Eising; Vicky Amo-Addae; Johanna Walther; Esmeralda Bosman; Zhiyong Lei; Olivier G de Jong; Jan J Molenaar; Enrico Mastrobattista

doi:10.1371/journal.pone.0332617

Loading metrics

Open Access

Peer-reviewed

Research Article

Anti-cancer compound screening identifies Aurora Kinase A inhibition as a means to favor CRISPR/Cas9 gene correction over knock-out

Danny Wilbie,

Roles Conceptualization, Investigation, Methodology, Writing – original draft

Affiliation Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands

https://orcid.org/0000-0003-1004-304X

⨯
Selma Eising,

Roles Conceptualization, Formal analysis, Methodology

Affiliation Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
⨯
Vicky Amo-Addae,

Roles Investigation, Methodology

Affiliation Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
⨯
Johanna Walther,

Roles Methodology

Affiliation Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands
⨯
Esmeralda Bosman,

Roles Investigation, Methodology

Affiliation Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands
⨯
Zhiyong Lei,

Roles Methodology, Resources

Affiliation CDL Research, University Medical Center Utrecht, Utrecht, the Netherlands
⨯
Olivier G de Jong,

Roles Resources, Writing – review & editing

Affiliation Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands
⨯
Jan J Molenaar,

Roles Conceptualization, Resources, Supervision

Affiliations Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
⨯
Enrico Mastrobattista

Roles Conceptualization, Supervision, Writing – review & editing

* E-mail: e.mastrobattista@uu.nl (EM)

Affiliation Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands
⨯

Anti-cancer compound screening identifies Aurora Kinase A inhibition as a means to favor CRISPR/Cas9 gene correction over knock-out

Danny Wilbie,
Selma Eising,
Vicky Amo-Addae,
Johanna Walther,
Esmeralda Bosman,
Zhiyong Lei,
Olivier G de Jong,
Jan J Molenaar,
Enrico Mastrobattista

Published: September 26, 2025
https://doi.org/10.1371/journal.pone.0332617

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Non-homologous end joining
Is the Subject Area "Non-homologous end joining" applicable to this article?

Thanks for your feedback.
Toxicity
Is the Subject Area "Toxicity" applicable to this article?

Thanks for your feedback.
DNA repair
Is the Subject Area "DNA repair" applicable to this article?

Thanks for your feedback.
CRISPR
Is the Subject Area "CRISPR" applicable to this article?

Thanks for your feedback.
Drug screening
Is the Subject Area "Drug screening" applicable to this article?

Thanks for your feedback.
Genetic loci
Is the Subject Area "Genetic loci" applicable to this article?

Thanks for your feedback.
Genomics
Is the Subject Area "Genomics" applicable to this article?

Thanks for your feedback.
Protein kinases
Is the Subject Area "Protein kinases" applicable to this article?

Thanks for your feedback.